HNF4A and prostate carcinoma: In addition to promising activity versus prostate cancer, macrocycles targeting β-catenin:TCF could also be of therapeutic benefit in other forms of cancer for which Wnt signaling is similarly pro-tumorigenic, such as colon and breast cancers.